The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis

References

• Goldschmidt C, McGinley MP. Advances in the treatment of multiple sclerosis. Neurol Clin. 2021;39:21–33. doi:10.1016/j.ncl.2020.09.002
   Web of Science ®Google Scholar
• Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. NDT. 2017;13:1349–1357. doi:10.2147/NDT.S132079
   Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46:907–911. doi:10.1212/WNL.46.4.907
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–286. doi:10.1212/WNL.0000000000000560
   PubMed Web of Science ®Google Scholar
• Wallin MT, Culpepper WJ, Nichols E; GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–285. doi:10.1016/S1474-4422(18)30443-5
   PubMed Web of Science ®Google Scholar
• EMSP, Multiple sclerosis in Europe. Available from: https://emsp.org/wp-content/uploads/2021/06/MS-in-EU-access. Accessed 12 December 2021.
   Google Scholar
• English C, Aloi JJ. New FDA-approved disease-modifying therapies for multiple sclerosis. Clin Ther. 2015;37:691–715. doi:10.1016/j.clinthera.2015.03.001
   PubMed Web of Science ®Google Scholar
• Finkelsztejn A. Multiple sclerosis: overview of disease-modifying agents. Perspect Medicin Chem. 2014;6:65–72. doi:10.4137/PMC.S13213
   Google Scholar
• Bergamasco R, Agnello M, Della Giovanna M, et al. Utilità dei database amministrativi per l’analisi del percorso effettivo del paziente con sclerosi multipla: identificazione dei marcatori di ricaduta clinica [Usefulness of administrative databases for the analysis of therapeutic patterns of patients witl multiple sclerosis: identification of markers of clinical relapse]. Supplemento A Politiche Sanitarie. 2012;13:1.
   Google Scholar
• Patti F, Amato MP, Trojano M, et al. Multiple sclerosis in Italy: cost-of-illness study. Neurol Sci. 2011;32:787–794. doi:10.1007/s10072-011-0499-2
   PubMed Web of Science ®Google Scholar
• Russo P, Capone A, Paolillo A, et al. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clin Drug Investig. 2004;24:409–420. doi:10.2165/00044011-200424070-00004
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler. 2012;18:29–34. doi:10.1177/1352458512441566c
   PubMed Web of Science ®Google Scholar
• Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47:S51–5. doi:10.1097/MLR.0b013e31819c95aa
   PubMed Web of Science ®Google Scholar
• Van Le H, Le Truong CT, Kamauu AWC, et al. Identifying patients with relapsing-remitting multiple sclerosis using algorithms applied to US integrated delivery network healthcare data. Value Health. 2019;22:77–84. doi:10.1016/j.jval.2018.06.014
   Web of Science ®Google Scholar
• Katz Sand I, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20:1654–1657. doi:10.1177/1352458514521517
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383. doi:10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Gupta SK. Intention-to-treat concept: a review. Perspect Clin Res. 2011;2:109–112. doi:10.4103/2229-3485.83221
   PubMedGoogle Scholar
• Wade BJ. Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Mult Scler Int. 2014;2014:1–7. doi:10.1155/2014/124578
   Google Scholar
• Browne P, Chandraratna D, Angood C, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83:1022–1024. doi:10.1212/WNL.0000000000000768
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021;17:676–688. doi:10.1038/s41582-021-00556-y
   PubMed Web of Science ®Google Scholar
• Battaglia M, Kobelt G, Ponzio M, et al. European multiple sclerosis platform. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler. 2017;23:104–116. doi:10.1177/1352458517708176
   PubMed Web of Science ®Google Scholar
• Bhatia R, Singh N. Can we treat secondary progressive multiple sclerosis now? Ann Indian Acad Neurol. 2019;22:131–136. doi:10.4103/aian.AIAN_345_18
   PubMed Web of Science ®Google Scholar
• D’Amico E, Ziemssen T, Cottone S. To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question. Expert Rev Neurother. 2017;17:847–849. doi:10.1080/14737175.2017.1340831
   PubMed Web of Science ®Google Scholar
• Cortesi GA, Cozzolino P, Capra R, et al. The economic burden of different multiple sclerosis courses: analysis from Italian administrative and clinical databases. Farmeconomia. 2020;21:49–58.
   Google Scholar
• Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: comparison between centre-based and local service healthcare delivery. PLoS One. 2019;14:e0222012. doi:10.1371/journal.pone.0222012
   PubMed Web of Science ®Google Scholar
• Fogarty E, Walsh C, McGuigan C, et al. Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy. 2014;12:635–645. doi:10.1007/s40258-014-0128-3
   PubMedGoogle Scholar
• Vestergaard SV, Rasmussen TB, Stallknecht S, et al. Occurrence, mortality and cost of brain disorders in Denmark: a population-based cohort study. BMJ Open. 2020;10:e037564. doi:10.1136/bmjopen-2020-037564
   Web of Science ®Google Scholar